Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Lee, Tim ^a   Southern, K W ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Cystic fibrosis transmembrane conductance regulator *genetics; therapeutic use ; Cystic fibrosis genetics; *therapy ; Gene therapy adverse effects; *methods ; Gene transfer techniques; Randomized controlled trials as topic

Indexed keywords

ERROR; REVIEW;

EID: 44949229208     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005599.pub2     Document Type: Review

References (50)

1. Alton 1999 {published data only} *Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, et al.Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. The Lancet 1999;353(9157): 947-54.
2. Davies MG, Stern M, Geddes DM, Alton EWFW. Reduction in sputum inflammatory cells and IL-8 following pulmonary administration of liposome mediated CFTR gene transfer in CF subjects [abstract]. Thorax 1998;53(Suppl 4):A14.
3. Stern M, Phillips J, Jaffe A, Farley R, Chadwick S, Davies J. A double blind placebo controlled trial of pulmonary and nasal administration of liposome-mediated CFTR gene transfer in CF subjects [abstract]. American Journal of Respiratory and Critical Care Medicine 1998;157 (3 Suppl):A564.
4. Stern M, Phillips J, Jaffe A, Farley R, Chadwick S, Davies J, et al. A double blind placebo controlled trial of pulmonary and nasal administration of liposome-mediated CFTR gene transfer in CF subjects [abstract]. Thorax 1997;52(Suppl 6):A3.
5. Moss 2004 {published data only} Moss RB, Aitken M, Clancy J, Milla C, Rodman D, Spencer T, et al.A multicenter, double-blind, placebo controlled, phase II study of aerosolized TGAAVCF in cystic fibrosis patients with mild lung disease [abstract]. Pediatric Pulmonology 2002;34(Suppl 24):250-1.
6. *Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, et al.Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004;125(2):509-21.
7. Moss 2007 {published and unpublished data} Moss RB, Heald AE, 25E01 Study Group. A randomized phase 2B study of aerosolized tgAAVCF for treatment of cystic fibrosis [abstract]. American Thoracic Society International Conference; 2005 May 20-25; San Diego, USA. 2005:A179.
8. Moss RB, Heald AE, 25E01 Study Group. Phase IIB Trial of Aerolsolized tfAAVCF for Cystic Fibrosis. Journal of Cystic Fibrosis 2005; 4(Suppl 1):S27.
9. *Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, et al.Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Human Gene Therapy 2007;18(8):726-32.
10. Moss RB, Milla C, Colombo J, Clancy JP, Zeitlin P, Spencer T, et al.A multicenter, double-blind, placebo-controlled, phase 2b study of aerosolized TGAAVCF for the treatment of cystic fibrosis [abstract]. Pediatric Pulmonology 2004;38(Suppl 27):257.
11. Flotte 1996 Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, et al.A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Human Gene Therapy 1996;7(9):1145-59. [MEDLINE: 96369511].
12. Gill 1997 *Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, Sorgi F, et al.A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Therapy 1997;4(3):199-209. [MEDLINE: 97281425].
13. Gill DR, Southern KW, Mofford KA, Sorgi F, Huang L, Higgins CF, et al.A Phase I clinical trial to assess the safety of DNA/liposome mediated gene transfer [abstract]. Pediatric Pulmonology 1996;22(Suppl 13):264.
14. Hyde SC, Southern KW, Mofford KA, Sorgi F, Huang L, Higgins CF, et al.Towards DNA/liposome gene therapy for cystic fibrosis: A phase I clinical trial [abstract]. Pediatric Pulmonology 1996;22(Suppl 13):265.
15. Harvey 1999 Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL, et al.Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus see comments. Journal of Clinical Investigation 1999;104 (9):1245-55.
16. Hyde 2000 *Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, et al.Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Therapy 2000; 7(13):1156-65.
17. Southern KW, Hyde SC, Fitzjohn EM, Waddell BE, Egan JJ, Cole JY, et al.Repeated nasal administration of liposome-mediated CFTR gene transfer reagents; the clinical and immunological consequences [abstract]. Pediatric Pulmonology 1997;24(Suppl 14):265.
18. Joseph 2001 Joseph PM, O'Sullivan BP, Lapey A, Dorkin H, Oren J, Balfour R, et al.Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Human Gene Therapy 2001;12(11):1369-82.
19. Knowles 1995 Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu PC, et al.A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. New England Journal of Medicine 1995;333(13):823-31.
20. Noone 2000 Noone PG, Hohneker KW, Gipson CA, Schwartzbach CJ, Efthimiou J, Johnson LG, et al.Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis [abstract]. Pediatric Pulmonology 1998;26(Suppl 17):260.
21. *Noone PG, Hohneker KW, Zhou Z, Johnson LG, Foy C, Gipson C, et al.Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Molecular Therapy 2000;1(1):105-14.
22. Porteous 1997 *Porteous DJ, Dorin JR, McLachlan G, Davidson Smith H, Davidson H, Stevenson BJ, et al.Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Therapy 1997;4(3):210-8. [MEDLINE: 97281426].
23. Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Davidson H, Stevenson BJ, et al.DOTAP catonic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis [abstract]. Pediatric Pulmonology 1996;22(Suppl 13):266.
24. Wagner 1999 *Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, Desch JK, et al.Safety and biological efficacy of an adeno-associated virus vector - cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 1999;109(2 Pt 1):266-74.
25. Wagner JA, Nepomuceno IB, Shah N, Messner AH, Moran ML, Norbash AM, et al.Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies. Journal of Gene Medicine 1999;1(1):13-21.
26. Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, Flotte TR, et al.Efficient and persistent gene transfer of AAV-CFTR inmaxillary sinus [letter]. Lancet 1998;351(9117):1702-3.
27. Wagner 2002 Wagner JA, Messner AH, Friborg S, Reynolds T, Guggino WB, Moss RB, et al.A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF in the maxillary sinus of CF patients [abstract]. Pediatric Pulmonology 1998;26(Suppl 17):260.
28. Wagner JA, Messner AH, Moran ML, Guggino WB, Flotte TR, Wine JJ, et al.A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in CF patients with antrostomies [abstract]. Pediatric Pulmonology 1999;28(Suppl 19):223-4.
29. *Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, et al.A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Human Gene Therapy 2002;13(11):1349- 59.
30. Zabner 1996 Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL, et al.Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. Journal of Clinical Investigation 1996;97(6):1504-11.
31. Zabner 1997 Zabner J, Cheng SH, Meeker D, Launspach J, Balfour R, Perricone MA, et al.Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. Journal of Clinical Investigation 1997;100(6):1529-37. [MEDLINE: 97439775].
32. Zuckerman 1999 *Zuckerman JB, Robinson CB, McCoy KS, Shell R, Sferra TJ, Chirmule N, et al.A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Human Gene Therapy 1999;10(18):2973-85.
33. Bobadilla 2002 Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic Fibrosis: A worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Human Mutation 2002;19(6):575- 606.
34. Boucher 2004 Boucher RC.New concepts of the pathogenesis of cystic fibrosis lung disease. European Respiratory Journal 2004;23(1): 146-58.
35. Conway 1994 Conway SP, Pond MN, Bowler I, Smith DL, Simmonds EJ, Joanes DN, et al.The chest radiograph in cystic fibrosis: A new scoring system compared with the Chrispin-Norman and Brasfield scores. Thorax 1994;49:860-2.
36. Elbourne 2002 Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
37. Ferrari 2002 Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Advanced Drug Delivery Reviews 2002;54(11):1373-93.
38. FitzSimmons 1993 FitzSimmons SC. The changing epidemiology of cystic fibrosis. Journal of Pediatrics 1993;122(1):1-9.
39. Frederiksen 1996 Frederiksen B, Lanng S, Koch C, Hoiby N. Improved survival in the Danish centre treated cystic fibrosis patients: Results of aggressive treatment. Pediatric Pulmonology 1996;21(3):153-8.
40. Griesenbach 2004 Griesenbach U, Geddes DM, Alton EW. Gene therapy for cystic fibrosis: an example for lung gene therapy. Gene Therapy 2004;11 (Suppl 1):S43-50.
41. Griesenbach 2005 Griesenbach U, Boyd AC. Pre-clinical and clinical endpoint assays for cystic fibrosis gene therapy. Journal of Cystic Fibrosis 2005;4:89-100.
42. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327 (7414):557-60.
43. Jüni 2001 Jüni P, Altman DG, Egger M. Systematic reviews in healthcare: Assessing the quality of controlled clinical trials. British Medical Journal 2001;323(7303):42-6.
44. Lee 2005 Lee TW, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochemical Journal 2005;387(Pt 1):1-15.
45. Matsui 1998 Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis W, et al.Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95(7):1005-15.
46. Ranganathan 2004 Ranganathan SC, Stocks J, Dezateux C, Bush A, Wade A, Carr S, et al.The evolution of airway function in early childhood following clinical diagnosis of cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2004;169(8):928-33.
47. Riordan 1989 Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al.Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245(4922): 1066-73.
48. Rowntree 2003 Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Annals of Human Genetics 2003;67(Pt 5):471-85.
49. Southern 1996 Southern KW. Gene therapy for cystic fibrosis: current issues. British Journal of Hospital Medicine 1996;55(8): 495-9.
50. Southern 2003 Southern KW, Smyth RL. Design of clinical trials in cystic fibrosis. Lancet 2003;360:978-84.